» Articles » PMID: 38195396

Diagnostic Accuracy of the Clock Drawing Test in Screening for Early Post-stroke Neurocognitive Disorder: the Nor-COAST Study

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2024 Jan 9
PMID 38195396
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Post-stroke neurocognitive disorder, though common, is often overlooked by clinicians. Moreover, although the Montreal Cognitive Assessment (MoCA) has proven to be a valid screening test for neurocognitive disorder, even more time saving tests would be preferred. In our study, we aimed to determine the diagnostic accuracy of the Clock Drawing Test (CDT) for post-stroke neurocognitive disorder and the association between the CDT and MoCA.

Methods: This study is part of the Norwegian Cognitive Impairment After Stroke study, a multicentre prospective cohort study following patients admitted with acute stroke. At the three-month follow-up, patients were classified with normal cognition, mild neurocognitive disorder, or major neurocognitive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. Any neurocognitive disorder compromised both mild- and major neurocognitive disorder. The CDT at the three-month assessment was given scores ranging from 0 to 5. Patients able to complete the CDT and whose cognitive status could be classified were included in analyses. The CDT diagnostic accuracy for post-stroke neurocognitive disorder was identified using receiver operating characteristic curves, sensitivity, specificity, positive predictive value, and negative predictive value. The association between the MoCA and CDT was analysed with Spearman's rho.

Results: Of 554 participants, 238 (43.0%) were women. Mean (SD) age was 71.5 (11.8) years, while mean (SD) National Institutes of Health Stroke Scale score was 2.6 (3.7). The area under the receiver operating characteristic curve of the CDT for major neurocognitive disorder and any neurocognitive disorder was 0.73 (95% CI, 0.68-0.79) and 0.68 (95% CI, 0.63-0.72), respectively. A CDT cutoff of < 5 yielded 68% sensitivity and 60% specificity for any neurocognitive disorder and 78% sensitivity and 53% specificity for major neurocognitive disorder. Spearman's correlation coefficient between scores on the MoCA and CDT was 0.50 (95% CI, 0.44-0.57, p < .001).

Conclusions: The CDT is not accurate enough to diagnose post-stroke neurocognitive disorder but shows acceptable accuracy in identifying major neurocognitive disorder. Performance on the CDT was associated with performance on MoCA; however, the CDT is inferior to MoCA in identifying post-stroke neurocognitive disorder.

Trial Registration: ClinicalTrials.gov (NCT02650531). Retrospectively registered January 8, 2016.

Citing Articles

Artificial intelligence detection of cognitive impairment in older adults during walking.

Obuchi S, Kojima M, Suzuki H, Garbalosa J, Imamura K, Ihara K Alzheimers Dement (Amst). 2024; 16(3):e70012.

PMID: 39328904 PMC: 11424983. DOI: 10.1002/dad2.70012.

References
1.
Kuvas K, Saltvedt I, Aam S, Thingstad P, Ellekjaer H, Askim T . The Risk of Selection Bias in a Clinical Multi-Center Cohort Study. Results from the Norwegian Cognitive Impairment After Stroke (Nor-COAST) Study. Clin Epidemiol. 2020; 12:1327-1336. PMC: 7718873. DOI: 10.2147/CLEP.S276631. View

2.
Paul R, Cohen R, Moser D, Zawacki T, Ott B, Gordon N . The global deterioration scale: relationships to neuropsychological performance and activities of daily living in patients with vascular dementia. J Geriatr Psychiatry Neurol. 2002; 15(1):50-4. DOI: 10.1177/089198870201500110. View

3.
Dong Y, Sharma V, Chan B, Venketasubramanian N, Teoh H, Seet R . The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci. 2010; 299(1-2):15-8. DOI: 10.1016/j.jns.2010.08.051. View

4.
Morris J, Mohs R, Rogers H, Fillenbaum G, HEYMAN A . Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull. 1988; 24(4):641-52. View

5.
Hachinski V, Iadecola C, Petersen R, Breteler M, Nyenhuis D, Black S . National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006; 37(9):2220-41. DOI: 10.1161/01.STR.0000237236.88823.47. View